Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 March 2006, Vol. 107, No. 5, pp. 1996-2003.
Prepublished online as a Blood First Edition Paper on October 27, 2005; DOI 10.1182/blood-2005-07-2926.


This Article
Right arrow Full Text (PDF)
Right arrow Erratum (v107,p2612)
Right arrow All Versions of this Article:
2005-07-2926v1
107/5/1996    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munitz, A.
Right arrow Articles by Levi-Schaffer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munitz, A.
Right arrow Articles by Levi-Schaffer, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted July 26, 2005
Accepted October 17, 2005

The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF and eotaxin on human peripheral blood eosinophils

Ariel Munitz, Ido Bachelet, Ron Eliashar, Alessandro Moretta, Lorenzo Moretta, and Francesca Levi-Schaffer*

Department of Pharmacology, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
Department of Otolaryngology-Head and Neck Surgery, Hebrew University School of Medicine, Hadassah Medical Center, Jerusalem, Israel
Dipartimento di Medicina Sperimentale, Universita degli Studi di Genova, Genova, Italy
Dipartimento di Medicina Sperimentale, Universita degli Studi di Genova, Genova, Italy; Istituto Gaslini, Genova, Italy
Department of Pharmacology, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel; The David R. Bloom Center for Pharmacology, The School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Israel

* Corresponding author; email: fls{at}cc.huji.ac.il.

Allergic, inflammatory and immune responses carried out by eosinophils are regulated by the cross-talk between activatory and inhibitory signals. While much data has been obtained on activatory signals, inhibitory receptors on these cells have received scant attention. Therefore, we screened the surface of human peripheral blood eosinophils for inhibitory receptors using mAbs previously generated to recognize receptors on human natural killer cells. Eosinophils from all of the donors examined expressed the inhibitory receptors IRp60, LIR3/ILT5, Fc{gamma}RIIB and p75/AIRM but not LIR1/ILT2, p58.1, p58.2, p70 or NKG2A/CD94 (n=15). Interestingly, 25% of the donors expressed p140. IRp60 cross-linking inhibited eotaxin-dependent transmigration of eosinophils in a calcium-independent fashion. In addition, cross-linking of IRp60 on the eosinophils in the presence of IL-5/GM-CSF inhibited the anti-apoptotic effect of these cytokines and blocked the release of TNF-{alpha}, IL-1{beta}, IFN-{gamma}IL-4 and 3T3 fibroblast proliferation. Cross-linking of IRp60 inhibited IL-5-mediated JAK2 phosphorylation as well as eotaxin- and IL-5/GM-CSF-mediated ERK1/2 and p38 phosphorylation. Furthermore, upon cross-linking, IRp60 underwent tyrosine phosphorylation and recruited SHP-1 but not SHP-2. These findings demonstrate a novel pathway for suppressing the activity of human eosinophils thus indicating IRp60 as a future potential target for the treatment of allergic and eosinophil-associated diseases.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
X. Ju, M. Zenke, D. N. J. Hart, and G. J. Clark
CD300a/c regulate type I interferon and TNF-{alpha} secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands
Blood, August 15, 2008; 112(4): 1184 - 1194.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
L. Mahajan, T. Madan, N. Kamal, V. K. Singh, R. B. Sim, S. D. Telang, C. N. Ramchand, P. Waters, U. Kishore, and P. U. Sarma
Recombinant surfactant protein-D selectively increases apoptosis in eosinophils of allergic asthmatics and enhances uptake of apoptotic eosinophils by macrophages
Int. Immunol., August 1, 2008; 20(8): 993 - 1007.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Munitz, M. L. McBride, J. S. Bernstein, and M. E. Rothenberg
A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils
Blood, June 15, 2008; 111(12): 5694 - 5703.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Bachelet, A. Munitz, B. Berent-Maoz, D. Mankuta, and F. Levi-Schaffer
Suppression of Normal and Malignant Kit Signaling by a Bispecific Antibody Linking Kit with CD300a
J. Immunol., May 1, 2008; 180(9): 6064 - 6069.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Yoon, A. Terada, and H. Kita
CD66b Regulates Adhesion and Activation of Human Eosinophils
J. Immunol., December 15, 2007; 179(12): 8454 - 8462.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Martinez-Losa, J. Cortijo, G. Juan, M. Ramon, M. J. Sanz, and E. J. Morcillo
Modulatory effects of N-acetyl-L-cysteine on human eosinophil apoptosis
Eur. Respir. J., September 1, 2007; 30(3): 436 - 442.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Izawa, J. Kitaura, Y. Yamanishi, T. Matsuoka, T. Oki, F. Shibata, H. Kumagai, H. Nakajima, M. Maeda-Yamamoto, J. P. Hauchins, et al.
Functional Analysis of Activating Receptor LMIR4 as a Counterpart of Inhibitory Receptor LMIR3
J. Biol. Chem., June 22, 2007; 282(25): 17997 - 18008.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Munitz, I. Bachelet, F. D. Finkelman, M. E. Rothenberg, and F. Levi-Schaffer
CD48 Is Critically Involved in Allergic Eosinophilic Airway Inflammation
Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 911 - 918.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Alvarez-Errico, J. Sayos, and M. Lopez-Botet
The IREM-1 (CD300f) Inhibitory Receptor Associates with the p85{alpha} Subunit of Phosphoinositide 3-Kinase
J. Immunol., January 15, 2007; 178(2): 808 - 816.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Shi, K. Luo, D. Xia, T. Chen, G. Chen, Y. Jiang, N. Li, and X. Cao
DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses
Blood, October 15, 2006; 108(8): 2678 - 2686.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Bachelet, A. Munitz, D. Mankutad, and F. Levi-Schaffer
Mast Cell Costimulation by CD226/CD112 (DNAM-1/Nectin-2): A NOVEL INTERFACE IN THE ALLERGIC PROCESS
J. Biol. Chem., September 15, 2006; 281(37): 27190 - 27196.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Munitz, I. Bachelet, R. Eliashar, M. Khodoun, F. D. Finkelman, M. E. Rothenberg, and F. Levi-Schaffer
CD48 Is an Allergen and IL-3-Induced Activation Molecule on Eosinophils
J. Immunol., July 1, 2006; 177(1): 77 - 83.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020